AC IMMUNE SA SF-02 (F:IMR) — Market Cap & Net Worth
Market Cap & Net Worth: AC IMMUNE SA SF-02 (IMR)
AC IMMUNE SA SF-02 (F:IMR) has a market capitalization of $233.21 Million (€199.48 Million) as of June 19, 2026. Listed on the F stock exchange, this Germany-based company holds position #16029 globally and #1540 in its home market, demonstrating a 6.75% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying AC IMMUNE SA SF-02's stock price €1.96 by its total outstanding shares 101773573 (101.77 Million). Review IMR total debt and obligations to assess the company's total debt and financial obligations.
AC IMMUNE SA SF-02 Market Cap History: 2016 to 2026
AC IMMUNE SA SF-02's market capitalization history from 2016 to 2026. Data shows change from $1.43 Billion to $233.21 Million (-18.76% CAGR).
AC IMMUNE SA SF-02 Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how AC IMMUNE SA SF-02's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
87.25x
AC IMMUNE SA SF-02's market cap is 87.25 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2022 | $201.14 Million | $3.94 Million | -$70.75 Million | 51.12x | N/A |
| 2023 | $511.63 Million | $14.80 Million | -$54.23 Million | 34.57x | N/A |
| 2024 | $301.03 Million | $27.31 Million | -$50.92 Million | 11.02x | N/A |
| 2025 | $311.74 Million | $3.57 Million | -$70.45 Million | 87.25x | N/A |
Competitor Companies of IMR by Market Capitalization
Companies near AC IMMUNE SA SF-02 in the global market cap rankings as of June 19, 2026.
Key companies related to AC IMMUNE SA SF-02 by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #221 globally with a market cap of $110.45 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #445 globally with a market cap of $62.84 Billion USD.
- UCB SA (BR:UCB): Ranked #547 globally with a market cap of $49.68 Billion USD ( €42.50 Billion EUR).
- Argen-X (BR:ARGX): Ranked #573 globally with a market cap of $47.14 Billion USD ( €40.32 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #221 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $110.45 Billion | $451.63 |
| #445 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $62.84 Billion | $609.94 |
| #547 | UCB SA | BR:UCB | $49.68 Billion | €249.20 |
| #573 | Argen-X | BR:ARGX | $47.14 Billion | €762.80 |
AC IMMUNE SA SF-02 Historical Marketcap From 2016 to 2026
Between 2016 and today, AC IMMUNE SA SF-02's market cap moved from $1.43 Billion to $ 233.21 Million, with a yearly change of -18.76%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | €233.21 Million | -25.19% |
| 2025 | €311.74 Million | +3.56% |
| 2024 | €301.03 Million | -41.16% |
| 2023 | €511.63 Million | +154.36% |
| 2022 | €201.14 Million | -61.40% |
| 2021 | €521.15 Million | +4.14% |
| 2020 | €500.45 Million | -43.05% |
| 2019 | €878.70 Million | -9.94% |
| 2018 | €975.67 Million | -21.53% |
| 2017 | €1.24 Billion | -13.18% |
| 2016 | €1.43 Billion | -- |
End of Day Market Cap According to Different Sources
On Jun 19th, 2026 the market cap of AC IMMUNE SA SF-02 was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $233.21 Million USD |
| MoneyControl | $233.21 Million USD |
| MarketWatch | $233.21 Million USD |
| marketcap.company | $233.21 Million USD |
| Reuters | $233.21 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About AC IMMUNE SA SF-02
AC Immune SA, a clinical stage biopharmaceutical company, discovers, designs, and develops medicines, and therapeutic and diagnostic products for the prevention and treatment of neurodegenerative diseases associated with protein misfolding. The company's SupraAntigen and Morphomer platforms are designed to generate biologics and small molecules, which selectively interact with misfolded proteins … Read more